The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Jeffrey Sum-Lung, Dong, Yawen, Tang, Vikki, Leung, Thomas, Yeung, Cynthia S. Y., Tai, Anna, Law, Ada, Shum, Tracy, Kwok, Gerry Gin-Wai, Li, Bryan Cho-Wing, Leung, Roland, Chiu, Joanne, Ma, Ka-Wing, She, Wong-Hoi, Tsang, Josephine, Cheung, Tan-To, Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/
https://www.ncbi.nlm.nih.gov/pubmed/33919277
http://dx.doi.org/10.3390/cancers13092002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/
https://www.ncbi.nlm.nih.gov/pubmed/33919277
http://dx.doi.org/10.3390/cancers13092002

Ejemplares similares